title: [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
abstract: OBJECTIVE
  Telbivudine is an L-nucleoside analogue with potent antiviral activity against hepatitis B virus (HBV). Clinical trials have shown that telbivudine is more potent than lamivudine for suppressing virus.
  
  
  METHODS
  A total 101 Korean patients among 1,367 patients who participated in the phase III GLOBE trial were randomized in this study. All 101 HBeAg positive or HBeAg negative patients were assigned to treatment with 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy endpoint (the "therapeutic response") was defined as suppression of the serum HBV DNA to less than 5 log10 copies/mL coupled with either normalization of the serum alanine aminotransferase level or loss of HBeAg. The secondary endpoints included the histologic response, serum HBV DNA reduction, serum alanine aminotransferase normalization and HBeAg loss for the HBeAg positive patients. This analysis includes the data collected at 52 weeks of treatment.
  
  
  RESULTS
  Fifty four of 101 patients were assigned to telbivudine treatment and 47 patients were assigned to lamivudine treatment. At week 52, significantly more patients who were treated with telbivudine than those treated with lamivudine had a therapeutic response (83% vs 62%, respectively, P=0.017), their mean serum HBV DNA levels were more reduced (6.6 vs 5.6 log10 copies/mL, respectively, P=0.027), and they more often achieved PCR-undetectable levels of serum HBV DNA (74% vs 34%, P<0.0001). No virologic resistance to telbivudine was detected (0% vs 18%, respectively, P=0.001). Telbivudine was well tolerated and it had a safety profile comparable to lamivudine.
  
  
  CONCLUSIONS
  Patients treated with telbivudine achieved earlier and more profound viral suppression than those treated with lamivudine.
authors.affiliation: Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea.
authors.forename: Young Myoung
authors.initials: YM
authors.lastname: Moon
authors.forename: Seong Gyu
authors.initials: SG
authors.lastname: Hwang
authors.forename: Boo Sung
authors.initials: BS
authors.lastname: Kim
authors.forename: Kyu Sung
authors.initials: KS
authors.lastname: Rim
authors.forename: Mong
authors.initials: M
authors.lastname: Cho
authors.forename: Dong Joon
authors.initials: DJ
authors.lastname: Kim
authors.forename: Joon Yeol
authors.initials: JY
authors.lastname: Han
authors.forename: Young Seok
authors.initials: YS
authors.lastname: Kim
authors.forename: Ho Soon
authors.initials: HS
authors.lastname: Choi
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Ahn
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000032:analysis; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005260:Female; D006513:Hepatitis B e Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007723:Korea; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D011744:Pyrimidinones; D000077712:Telbivudine; D019259:Lamivudine; D000410:Alanine Transaminase; D013936:Thymidine